异环基架的结构修改:抗菌药物发现的战略
Raksha Gupta1, Anubhuti Koshle1, Santosh Kumar Verma2
1Department of Chemistry, Shri Rawatpura Sarkar University, Raipur, Chhattisgarh, India.
Archiv der Pharmazie
|November 3, 2025
概括
新型电子吸收组 (EWG) 在增强抗生素对MRSA等多药耐药细菌的有效性方面表现有前途. 这项研究探讨了它们在开发新抗菌药物以对抗不断增加的感染中的作用.
科学领域:
- 药用化学 医学化学
- 细菌学 细菌学是一门学科.
- 药物发现 药物发现 药物发现
背景情况:
- 耐多药性 (MDR) 细菌感染,特别是耐甲基金色葡萄球菌 (MRSA),构成了严重的全球健康威胁.
- MRSA 呈现出对现有抗生素 (包括万科米辛) 的快速耐药性演变,需要开发新型治疗剂.
- 迫切需要新的,有效的,更安全的抗生素来对抗具有挑战性的细菌病原体.
研究的目的:
- 审查将电子提取组 (EWG) 纳入药物化学中的潜在好处,以发现抗菌药物.
- 探索 EWG 如何提高潜在抗生素候选剂对细菌病原体的疗效和药理动力学特性.
- 突出EWG在开发针对多药耐药细菌感染的新型治疗方法的战略性使用.
主要方法:
- 文献综述,重点关注电子提取组 (EWG) 在药物化学中的作用.
- 分析 EWG 如何影响小分子的物理化学和药理动力学特性.
- 检查表明EWG对各种病原体抗菌活性的影响的研究.
主要成果:
- 电子提取组 (EWGs),如-Cl,NO2,F和Br,可以显著提高候选药物的抗菌有效性.
- 战略性地放置EWG可以增强关键性质,如膜透性和代谢稳定性,这对于对抗MRSA至关重要.
- 审查表明,EWG在克服细菌耐药机制方面具有很大的潜力.
结论:
- 电子提取组 (EWG) 是增强抗菌功效和克服药物发现中的抗药性的一种有希望的策略.
- 针对性地应用EWG可以导致开发更有效,更稳定的抗微生物药物来对抗具有挑战性的感染.
- 为了开发下一代抗生素来对抗MDR细菌,对EWG修饰化合物的进一步研究是有必要的.
相关概念视频
Structure-Activity Relationships and Drug Design
1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Five-Membered Heterocyclic Aromatic Compounds: Overview
5.2K
Heterocyclic aromatic compounds are cyclic compounds that are aromatic and have one or more heteroatoms—atoms other than carbon, in the ring. Depending upon the number of atoms present in the ring, they can be either five or six-membered. Examples of five-membered heterocyclic aromatic compounds include pyrrole, furan, thiophene, and imidazole. Pyrrole consists of one nitrogen atom having one lone pair of electrons. Furan and thiophene have one oxygen and one sulfur heteroatom,...
5.2K
Diels–Alder Reaction Forming Bridged Bicyclic Products: Stereochemistry
5.3K
Diels–Alder reactions between cyclic dienes locked in an s-cis configuration and dienophiles yield bridged bicyclic products.
5.3K
Nomenclature of Aryl and Heterocyclic Amines
3.0K
The simplest aromatic amine is phenylamine, which contains an –NH2 functionality directly attached to an aromatic ring. The name aniline is designated for this skeleton. As shown in Figure 1, the common names of the functionalized anilines involve prefixes ortho-, meta-, and para- to indicate the substitution position. Different functionalized aniline derivatives also have notable trivial names.
3.0K
Basicity of Heterocyclic Aromatic Amines
6.8K
Heterocyclic amines, where the N atom is a part of an alicyclic system, are similar in basicity to alkylamines. Interestingly, the heterocyclic amine having a nitrogen atom as part of an aromatic ring has much less basicity than its corresponding alicyclic counterpart. For this reason, as presented in Figure 1, piperidine (pKb = 2.8) is significantly more basic than pyridine (pKb = 8.8).
6.8K
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K


